- Home
- NVA vs RPTX Comparison
NVA vs RPTX Comparison
Compare NVA & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVA
- RPTX
- Stock Information
- Founded
- NVA 1987
- RPTX 2016
- Country
- NVA Australia
- RPTX Canada
- Employees
- NVA N/A
- RPTX N/A
- Industry
- NVA
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- NVA
- RPTX Health Care
- Exchange
- NVA NYSE
- RPTX Nasdaq
- Market Cap
- NVA 62.5M
- RPTX 54.0M
- IPO Year
- NVA N/A
- RPTX 2020
- Fundamental
- Price
- NVA $11.88
- RPTX $1.29
- Analyst Decision
- NVA
- RPTX Strong Buy
- Analyst Count
- NVA 0
- RPTX 3
- Target Price
- NVA N/A
- RPTX $7.00
- AVG Volume (30 Days)
- NVA 31.0K
- RPTX 231.9K
- Earning Date
- NVA 01-01-0001
- RPTX 03-03-2025
- Dividend Yield
- NVA N/A
- RPTX N/A
- EPS Growth
- NVA N/A
- RPTX N/A
- EPS
- NVA N/A
- RPTX N/A
- Revenue
- NVA N/A
- RPTX $66,524,000.00
- Revenue This Year
- NVA N/A
- RPTX $12.15
- Revenue Next Year
- NVA N/A
- RPTX N/A
- P/E Ratio
- NVA N/A
- RPTX N/A
- Revenue Growth
- NVA N/A
- RPTX 18.19
- 52 Week Low
- NVA $4.35
- RPTX $1.10
- 52 Week High
- NVA $19.00
- RPTX $7.45
- Technical
- Relative Strength Index (RSI)
- NVA N/A
- RPTX 47.52
- Support Level
- NVA N/A
- RPTX $1.13
- Resistance Level
- NVA N/A
- RPTX $1.37
- Average True Range (ATR)
- NVA 0.00
- RPTX 0.09
- MACD
- NVA 0.00
- RPTX 0.04
- Stochastic Oscillator
- NVA 0.00
- RPTX 57.14
About NVA NOVA MINERALS LTD SPON ADS EACH REP 60 ORD
Nova Minerals Ltd is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project. It includes projects such as Estelle Gold and Critical Minerals Project, RPM, Korbel, Train and Stoney. It operates in one segment which is exploration of minerals and two geographical areas, being Australia and United States, where Australia derives maximum revenue.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.